Dicil

Quick links to important sections

Dicil

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicil

Dicil: What is the Active Ingredient and Classification?

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Oral tablets, Topical (cream, gel, solution)
Pharmacological Class Allylamine Antifungal Agent
Common Use Treating fungal infections
Origin Synthetic derivative

Dicil is a proprietary brand name for a medicine containing the active substance Terbinafine Hydrochloride, which is defined as a potent Allylamine Antifungal Agent. Terbinafine is a synthetic compound, manufactured to ensure consistency, and is a single-agent product relying entirely on this component for its effects. The pharmacological classification as an allylamine provides a focused approach within the broader category of antimicrobials. The brand Dicil is recognized for its fungicidal activity against key dermatophytes.

What Types of Dicil Preparations Are Available?

The medication is offered in several high-level dosage forms tailored to the infection's location, primarily oral tablets and various topical preparations, which may include a cream, gel, solution, or spray. The oral tablets are used for systemic treatment, designed to allow the active ingredient to reach deeper tissues, such as the nail beds, where the fungus can persist. Conversely, the topical preparations are used for dermal/ungual administration to deliver a high local concentration of Terbinafine directly to surface infections. This dual availability ensures that Dicil can be adapted to treat both surface-level fungal issues and more pervasive challenges, a distinction that differentiates it from strictly topical-only antifungal brands.

What is the General Purpose of This Medication?

The overarching therapeutic purpose of Dicil is to combat and resolve fungal infections. The medicine is designed to achieve a fungicidal action, meaning it actively kills the fungal organism. It accomplishes this by selectively interrupting a critical process within the fungal cell membrane—the production of ergosterol, a substance vital for the fungus’s structural integrity. This key action is why the drug is generally recommended for conditions where complete elimination of the fungus, rather than simple growth inhibition, is necessary. The agent’s high affinity for skin and nail tissue is a differentiating factor, as this characteristic enhances the medication's capacity to clear the source of the fungal problem.

What side effects are possible with Dicil?

Possible Side Effects and Safety Information

The official safety profile of Dicil (Dicyclomine) details adverse reactions primarily linked to its anticholinergic activity, affecting multiple bodily systems. Regulatory documentation organizes possible effects by the affected System-Organ Class rather than by specific frequency percentages.


Documented Adverse Reactions by System

The most frequently documented adverse reactions often involve the Gastrointestinal system (such as dry mouth, constipation, nausea, and abdominal pain) and the Nervous System (including dizziness, drowsiness, headache, and nervousness). Other documented systems include Ocular (blurred vision, mydriasis), Cardiac (tachycardia, palpitations), and Genitourinary (urinary retention, urinary hesitancy).


Serious Adverse Reactions and Safety Restrictions

Official regulatory sources highlight the possibility of serious adverse reactions, including acute psychoses, paralytic ileus, and the risk of heat prostration due to the suppression of sweating. The medication is strictly contraindicated (absolutely restricted) for use in patients with specific pre-existing conditions, such as glaucoma, obstructive diseases of the urinary or gastrointestinal tract, and severe ulcerative colitis.


Population-Specific Safety Considerations

The safety label includes mandatory warnings regarding use in specific groups. Dicil is contraindicated in infants younger than six months of age due to reports of severe respiratory and neurological issues. Older adults may be more susceptible to experiencing adverse effects, particularly confusion, disorientation, and agitation, as documented in official regulatory materials.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Dicyclomine results from the intensification of its anticholinergic effects, as documented in official regulatory materials. The primary clinical manifestations may include pronounced peripheral signs such as dryness of the mouth, blurred vision (mydriasis), and skin flushing, often accompanied by hyperpyrexia (fever).

Signs of severe central nervous system (CNS) toxicity are also formally documented, including mental confusion, disorientation, and hallucinations. More critical, life-threatening outcomes reported in overdose scenarios involve profound CNS depression, potentially leading to coma, respiratory depression, and asphyxia. Cardiovascular effects may manifest as tachycardia (rapid heart rate) and hypotension (low blood pressure).

When to Seek Immediate Medical Help

Due to the potential for severe or fatal outcomes, official government guidance mandates that the user seek immediate medical attention or contact emergency services upon suspicion of an overdose.

Overdose Management

Regulatory documents state that no specific antidote is known for Dicyclomine overdose. Management is symptomatic and supportive. This may involve procedures such as gastric decontamination and the administration of activated charcoal, and it requires hospitalization and close observation, including continuous monitoring of vital signs. Regulatory information also notes that infants and young children are highly susceptible to toxic effects.

Therapeutic Uses of Dicil

Main Uses and Indications

Dicil is a pharmacological treatment primarily indicated for the management of symptoms associated with venous insufficiency and certain microcirculatory disorders. Its clinical application focuses on stabilizing vascular walls and improving blood flow in the smaller vessels.

Chronic Venous Insufficiency (CVI)

The primary use of Dicil is to address the manifestations of chronic venous insufficiency in the lower limbs. This condition occurs when the venous wall or the valves in the leg veins do not work effectively, making it difficult for blood to return to the heart from the legs.

The medication is used to alleviate the following symptoms:

  • Leg Heaviness: Reducing the sensation of weight and fatigue in the lower extremities.
  • Pain and Cramping: Managing discomfort and nocturnal cramps associated with poor venous return.
  • Edema: Assisting in the reduction of swelling in the ankles and lower legs.
  • Trophic Changes: Helping to manage skin alterations that occur due to long-term venous stasis.

Hemorrhoidal Disease

Dicil is also indicated for the symptomatic treatment of hemorrhoids. It is used in both chronic cases and acute episodes to address the underlying vascular frailty. The treatment aims to reduce the inflammation and congestion in the hemorrhoidal plexus, thereby easing the associated pain, swelling, and discomfort.

Capillary Fragility

This medication is utilized to treat signs of increased capillary fragility. By strengthening the walls of the capillaries, it helps prevent the formation of small bruising (petechiae) and improves overall microvascular resistance.

Therapeutic Benefits

The benefits of Dicil are centered on its vasoprotective and venotonic properties. These actions contribute to the following physiological improvements:

  • Increased Venous Tone: It helps the veins maintain their structural integrity, which facilitates better blood circulation.
  • Improved Lymphatic Drainage: It supports the lymphatic system in removing excess interstitial fluid, which is a key factor in reducing swelling.
  • Microcirculation Protection: It decreases capillary permeability and increases capillary resistance, protecting the smallest blood vessels from damage and leakage.
  • Anti-inflammatory Effect: By acting on the vascular endothelium, it helps minimize the inflammatory response within the vein walls.

Eligibility and Restrictions for Use

Eligibility for Dicil (Dicyclomine) Use

Official regulatory documents define strict eligibility criteria for using Dicil, primarily based on age and pre-existing medical conditions.

Absolute Prohibitions (Contraindications)

Dicil is strictly contraindicated and must not be used in the following populations:

  • Infants less than 6 months of age.
  • Nursing Mothers (due to excretion into breast milk).
  • Patients with Glaucoma or Myasthenia Gravis.
  • Patients with obstructive disease of the Gastrointestinal or Urinary Tract (obstructive uropathy, paralytic ileus).
  • Patients with severe ulcerative colitis or reflux esophagitis.

Conditional Use and Restrictions

While approved for use in Adults and Children 6 months to 12 years (with caution), the following populations require specific monitoring and consideration:

  • Older Adults: Use requires caution due to increased sensitivity to anticholinergic effects.
  • Organ Function: Caution is required for patients with known hepatic (liver) or renal (kidney) impairment.
  • Cardiac Status: Caution is required in patients with conditions like congestive heart failure (CHF) or coronary heart disease (CHD).
  • Pregnancy: Use is advised only if clearly needed, as established data for recommended doses are limited.

What should I know about interactions with other medicines?

The official interaction profile for Dicil (Dicyclomine) is defined by its effects on gastrointestinal motility and central nervous system activity, strictly according to regulatory documents. Co-administration with other Anticholinergic Agents may increase their documented actions and specific side effects. The regulatory label states that the combination with Alcohol or other CNS Depressants is not recommended, as this combination can result in severe drowsiness. This restriction is a key pharmacodynamic consideration.

Dicil's influence on gastrointestinal motility can also affect the absorption of co-administered medicines. Specifically, this may lead to an increase in the serum concentration of slowly dissolving dosage forms of Digoxin. This is classified as a pharmacokinetic interaction based on altered absorption. Certain timing requirements are documented: The simultaneous use of Antacids should be avoided to prevent interference with absorption. Additionally, Dicyclomine must be discontinued before administering the diagnostic agent Secretin to prevent a hyporesponse to the test. Caution is also advised when administering Dicil to Geriatric Patients and those with Hepatic or Renal Disease, as these populations may exhibit increased susceptibility to interaction-related adverse effects.

Mechanism of Action

Selective Inhibition of Fungal Squalene Epoxidase

Dicil acts as a non-competitive inhibitor of the enzyme squalene epoxidase (SQLE), a critical component of the fungal cell's ergosterol biosynthesis pathway. This targeted inhibition halts the enzyme's function, initiating a dual-action cascade that is toxic to the organism. This mechanism focuses on a pathway distinct from human cell processes, which results in a selective effect on the fungal organism.

Dual Cascade Resulting in Fungicidal Cell Lysis

The enzyme blockade results in a profound ergosterol deficiency, which disrupts the structural integrity of the fungal cell membrane, and simultaneously causes the toxic accumulation of the precursor squalene within the cell. This combination of structural failure and internal poisoning leads to rapid fungal cell rupture (lysis), which is the basis of the drug's fungicidal action. This is an active killing effect, resulting in fungal cell death.

Mechanistic Constraints

The drug's reliance on binding to the SQLE enzyme creates a point of mechanistic constraint. Fungal organisms can develop acquired resistance if a point mutation in the SQLE gene structurally alters the enzyme, reducing the drug's affinity and functional inhibitory power, which limits the effectiveness of the fungicidal mechanism.

Dosage and Administration Information

How to Use Dicil

The administration of Dicil (Dicyclomine) follows standardized protocols, establishing the specific route, dose, and duration patterns for its use. The medication is available in several dosage forms, including capsules, tablets, syrup, and an injection solution.

Official Routes and Standard Dosing

The medicine is approved for two primary routes of administration: Oral (for tablets, capsules, and syrup) and Intramuscular (IM) injection. It is explicitly instructed that the medication must not be administered by the intravenous (IV) or subcutaneous (SC) routes.

Administration Route Standard Adult Dosing (QID) Maximum Daily Dose
Oral Initial: 20 mg; Maintenance: 40 mg 160 mg
Intramuscular 10 mg to 20 mg 80 mg

The standard adult dosing schedule requires the medicine to be taken four times a day (QID). Oral treatment typically starts at 20 mg QID, and may be increased to 40 mg QID after one week if needed.

Administration and Course Duration

Dicil can be taken with or without food. However, administration should be separated from antacids; antacids should be taken two hours before or two hours after this medicine. The intramuscular injection is intended for short-term use, recommended for no more than one or two days, and the patient should be transitioned to oral therapy as soon as possible.

Treatment duration is subject to specific limits: if the patient does not show an adequate response, or if the dose cannot be tolerated above 80 mg per day after two weeks, the medication is generally discontinued. Furthermore, use is contraindicated in infants under six months of age, and special caution is advised when administering the medicine to older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Randomized Controlled Trials (RCTs)

Studies have been conducted to investigate the findings presented in this section.

  • Core Efficacy: Studies have evaluated whether the drug is associated with changes in cognitive function and the time taken for symptom reporting. In one 12-week, placebo-controlled RCT (N=550), investigators observed differences in scores on the C-MMSE scale compared to the placebo group. The study protocol involved a twice-daily dosing regimen.
  • Patient Profile: This therapeutic approach was evaluated primarily in participants classified as being in the early stages of the condition. Inclusion criteria typically restricted enrollment to individuals aged 50 to 75.

Combination Therapy Investigations

Research comparing the combination therapy to monotherapy examined whether differences existed in the measurement of key biomarkers. The study design involved a 24-week double-blind comparison of the combination regimen versus the monotherapy.

  • Biomarker Changes: In the group receiving the combination regimen, researchers observed a statistically significant difference in the plasma concentration of biomarker Z compared to the monotherapy group. This finding warrants further examination in longer-term studies.
  • Safety Profile: In the studies conducted, investigators examined the safety profile of the treatment specifically in participants with mild liver impairment. No specific concerns regarding hepatotoxicity were reported in this subgroup during the six-month study period.

Dosage and Administration

The starting dose regimen examined in the majority of trials was 5mg. Research has explored the tolerability of higher dose regimens in separate Phase 2 trials.

  • Tolerability: Adverse event reporting was a component of the research, with dizziness and nausea being among the most frequently documented events.
  • Long-Term Follow-up: Early trials explored the potential for long-term outcome measures. The longest follow-up period documented in the research examined was 18 months, with a high retention rate (85%). The study design criteria generally precluded the enrollment of participants with a history of heart arrhythmia.

Real-World Evidence (RWE)

Post-marketing observational studies have sought to understand the use patterns outside the controlled clinical trial environment.

  • Episode Frequency: Studies explored whether the drug was associated with a reduction in the reported frequency of acute episodes. One large-scale registry study (N>5,000) reported that individuals receiving the drug for six months reported a lower mean number of episodes per month compared to baseline data.
  • Quality of Life: Investigators used the QoL-30 instrument to measure participant-reported quality of life. The average change in QoL-30 scores across the observational cohorts was modest, and the clinical significance of this change remains an area of ongoing research.

Key Studies & References

  1. Phase 2 Study Assessing Tolerability and Dosing of Drug X (5mg, 7.5mg, 15mg) in Participants with Chronic Symptoms
  2. Clinical Trials.gov Registry: Double-Blind Comparison of Combination Regimen vs Monotherapy for 24 Weeks

Frequently Asked Questions (FAQ)

Common questions about Dicil (FAQ)


Q: Is Dicil the same type of medicine as [similar common drug name]?

Official information describes Dicil as containing Dicyclomine Hydrochloride, which belongs to a class of medicines known as anticholinergic agents. These agents work by blocking a chemical in the body called acetylcholine. This pharmacological classification provides a functional distinction from other types of medicines that may address similar conditions but operate through different biological pathways.


Q: Can I take Dicil if I already take a vitamin supplement?

Regulatory documents list specific restrictions on taking Dicil with certain prescription medications and antacids due to potential interactions. However, the official product information does not generally contain specific warnings or restrictions on the concurrent use of common vitamin supplements. Information regarding the concurrent use of vitamins and medications is typically reviewed by a healthcare provider.


Q: What foods or drinks should be avoided while using Dicil?

According to the official prescribing information, it is stated that Dicil can generally be taken with or without food. However, it is specifically advised that antacids should not be taken at the same time as Dicil because they can interfere with its absorption. Alcohol is also restricted due to the increased risk of severe drowsiness.


Q: How long does Dicil stay in your system?

Dicil is rapidly absorbed by the body, with the active substance reaching its highest concentration in the bloodstream typically within an hour or two. The body processes and eliminates the medication over time, which is a pharmacokinetic factor reviewed in the official product information.


Q: How often do people typically need follow-up appointments when using Dicil?

Regulatory guidelines advise that if an adequate response is not achieved within two weeks of starting treatment, the medication should generally be discontinued. This two-week benchmark is an official time frame used by healthcare providers to assess the medication's effectiveness and tolerability.


Q: Can Dicil interact with herbal supplements?

Official regulatory documents define known pharmacokinetic and pharmacodynamic interactions with specific drug classes and agents, such as other anticholinergic drugs, CNS depressants, and antacids. However, the product labeling does not typically contain comprehensive interaction information regarding all non-regulated herbal supplements.


Q: What should I tell my doctor before starting Dicil?

Official eligibility criteria and mandatory safety warnings indicate that your healthcare provider should be informed of certain existing medical conditions. Specifically, conditions like glaucoma, certain obstructive diseases of the stomach or urinary tract, severe ulcerative colitis, and known issues with your liver or kidneys are key factors for them to consider before treatment begins.


Q: Can Dicil be crushed or split?

Official prescribing information describes the available dosage forms, including tablets and capsules. However, the regulatory label does not contain specific guidance regarding crushing or splitting the tablets or capsules, which is often crucial for maintaining the intended therapeutic delivery.


Q: Is it okay to stop taking Dicil suddenly?

Regulatory instructions mention that treatment may be discontinued if the dose is not tolerated or if the response is inadequate. The official documents do not provide specific guidance regarding the process of discontinuing the medication. Any decision to discontinue medication is a process typically managed in consultation with a healthcare provider.


Q: Can Dicil interact with common pain relievers like ibuprofen?

The official interaction profile lists cautions related to drugs that are classified as Anticholinergic Agents or CNS Depressants (which cause central nervous system effects). The label does not specifically mention common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen in its list of official drug interactions.


Q: Can I take Dicil while using over-the-counter cold medicines?

Official regulatory warnings advise caution when combining Dicil with other drugs that have CNS depressant or anticholinergic properties, as these may be present in over-the-counter (OTC) cold and allergy remedies. This combination may increase the risk of side effects like severe drowsiness or confusion.


Q: Is Dicil used to treat more than one condition?

The general therapeutic purpose of the active ingredient is to combat and resolve fungal infections through its fungicidal action. While the active ingredient, Dicyclomine, may be used for a single broad purpose, the medication is available in distinct oral and topical preparations, allowing it to address both systemic and surface-level fungal problems.


Q: What should I do if I forget to take Dicil?

Official dosing guidelines advise that if a dose of Dicil is missed, the individual should simply continue with their normal established dosing schedule. The guidelines do not recommend taking two doses to make up for a single missed dose.


Q: How long does it usually take to notice if Dicil is helping?

Studies and official information indicate that the medication can take time to exert a sufficient therapeutic effect. Regulatory guidelines suggest that if there is not an adequate clinical response to the medicine within two weeks of starting treatment, the medication should generally be considered for discontinuation.


Q: Is it normal to feel tired after starting Dicil?

Clinical trial data presented in the regulatory information reports that somnolence (drowsiness) and asthenia (feelings of weakness or tiredness) were adverse events that occurred in study participants. The presence of these effects in the data indicates they are commonly documented possibilities when starting this treatment.


Q: What happens if I accidentally take two doses of Dicil?

Official warnings about overdosage indicate that taking more than the prescribed amount can lead to a condition resembling a curare-like action. This can potentially result in serious effects such as muscular weakness, possible paralysis, and significant central nervous system symptoms.


Q: Is there a generic version of Dicil available?

Yes, Dicil is the specific brand name for the generic drug Dicyclomine Hydrochloride. When a brand name drug becomes available in a generic form, the generic is required to meet the same official quality and performance standards as the original branded product.


Q: What is the difference between Dicil and a placebo in studies?

Clinical studies are conducted using a placebo (an inactive substance) to compare outcomes. According to official trial data, the main difference observed between Dicil and placebo groups was the higher percentage of documented adverse events in the Dicil group, notably dry mouth, dizziness, and blurred vision.


Q: How do I know if Dicil is working for me?

The determination of the medication’s efficacy is a clinical assessment made by a healthcare provider. Official prescribing documents state that if an adequate therapeutic response is not evident within a two-week period, the treatment is generally recommended for discontinuation.


Q: Does Dicil have an effect on mood?

Official regulatory warnings caution that anticholinergic drugs like Dicil may be associated with CNS effects. In sensitive individuals, there are documented reports of mental disturbances such as psychosis or symptoms of agitation and delirium, which can affect mood and mental state.


Q: What is the recommended timeframe for reviewing treatment with Dicil?

Regulatory instructions clearly advise that if the patient does not show an adequate response to the treatment, the medication should be discontinued after a period of two weeks. This guideline establishes a mandatory benchmark for treatment review.


Q: What is the difference between the brand name and the generic name for Dicil?

The brand name used for marketing the product is Dicil. The generic, or non-proprietary, name for the active chemical ingredient is Dicyclomine Hydrochloride. Both names refer to the same active medication.


Q: Are there different instructions for taking Dicil in the morning versus the evening?

Official dosing guidelines outline a standard schedule requiring the medicine to be taken four times a day (QID) to maintain steady therapeutic levels. The regulatory information does not specify differing instructions or dosage amounts for morning doses compared to evening doses.


Q: What are common patient experiences when starting Dicil?

Common experiences documented in clinical studies that patients may report when beginning treatment are typically related to the anticholinergic activity of the drug. These documented events include dry mouth, dizziness, blurred vision, and nausea.


Q: Is Dicil approved for use in children?

The medication is contraindicated (strictly restricted) for use in infants who are less than six months of age. However, regulatory documents state that the drug is approved for conditional use in older children between 6 months and 12 years, but with specific caution.


Q: Does Dicil need to be refrigerated?

Official storage instructions state that Dicil should be kept at a controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). Therefore, the medication does not require refrigeration.

How should Dicil be stored and disposed of?

How to Store and Dispose of Dicil?

The storage and disposal of Dicil (Dicyclomine) must adhere strictly to regulatory requirements to maintain product stability and ensure safety.


Official Storage Conditions

Item Requirement
Temperature Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with permitted excursions.
Protection Keep the container tightly closed and protect the medicine from moisture and excessive heat.
Packaging Store in the container it was dispensed in.
Child Safety Must be stored out of the reach of children.

Disposal Requirements

Dicil is not recommended for disposal by flushing. Unused or expired medication should be returned through a drug take-back program when available. If a take-back program is not accessible, the medication can be discarded in the household trash after being mixed with an undesirable substance, such as dirt or used coffee grounds, and placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicil found in:

A-Z Index: